Novo Nordisk and Jia ®'s listing application in China approved by NMPA
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the StateDrug(http://Regulatory Authority (NMPA) approved the launch of Novo nord nordCompany's(http://of the Novo and Jia® (Degumen Winter Double Insulin Injection) in China for the treatment of type 2 diabetes in adultsit is understood that Noand® was included in the national priority review approval list in September last year, speeding up the pace of listing approval in ChinaThe Noande-Kamen-d'Oto-® (Degumen Winter Double Insulin Injection) consists of 70% Degu insulin and 30% of TheMenwinter insulin, but the two components of Degumen Winter Double Insulin are structurally undisturbedProfessor Wenying Yang, a former chairman of the Diabetes Branch of the Chinese Medical Association and director of the Endocrine Metabolism Center of the Sino-Japanese Friendship Hospital, said: "Degumen winter double insulin can significantly reduce the occurrence of hypoglycemia while using less insulin doses to achieve effective hypoglycemia, and the approval of degumen winter double insulin in China will bring more benefits to blood sugar management in patients with type 2 diabetes in China." "
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
